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Statement of Technology Practice
Executive Committee
On September 18, 1996, a report describing a potential
increase in morbidity and mortality associated with the use
of the pulmonary artery balloon catheter in critically ill
patients was published in the Journal of the American
Medical Association (1). The publication of this report was
accompanied by a call for a moratorium on the use of the
pulmonary artery balloon catheter until its effectiveness
could be documented in appropriately conducted trials,
particularly, randomized studies in critically ill patients (2).
The American College of Cardiology (ACC) subsequently
received a number of requests for statements and clarifica-
tions of its position on the use of the pulmonary artery
This Expert Consensus Document was approved by the American College of
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balloon catheter. In response to these requests, the Tech-
nology and Clinical Practice Executive Committee (TPEC)
of the ACC recommended to its Board of Trustees in
November 1996 that an Expert Consensus Document be
developed in response to this question. The TPEC ap-
pointed a panel of experts to provide peer comments on the
study by Connors et al (1), and to reassess the role of
bedside right heart catheterization in patients with cardiac
disease. This Expert Consensus Document underwent anon-
ymous external review and subsequent review by both the
TPEC and the Board of Trustees of the ACC. The document
was approved for publication in March 1998.
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Present Use of Bedside Right Heart Catheterization in Patients With
Cardiac Disease
Executive Summary
Bedside right heart catheterization (RHC) has been an
integral part of cardiovascular practice since the early 1970s.
Advances in diagnostic and treatment strategies, including
improved noninvasive imaging by Doppler echocardiography
and more prevalent use of coronary revascularization by
pharmacologic and catheter-based techniques, have changed
the role of RHC. A recent case-control study by Connors et al.
(1) questioned the safety and efficacy of RHC. The Expert
Consensus Committee, convened to develop this document,
was charged with two related tasks: 1) to provide peer com-
ments on the study by Connors et al. (1); and 2) to reassess the
role of RHC in patients with cardiac disease, providing recom-
mendations for current use and future research. There is a
paucity of objective information, particularly of outcome data,
derived from clinical trials. There is considerable variation
among physicians and nurses in the quality of acquisition and
interpretation of the data obtained. These differences create
certain difficulties regarding recommendations for the use of
RHC, as well as for the planning of multicenter clinical trials.
They also emphasize the need for education of physicians and
other health professionals in the use of RHC.
Evaluation of case-control study by Connors et al. (1). The
Expert Consensus Committee addresses the following issues:
1) RHC is a diagnostic and monitoring device and as such
potentially affects outcome only to the extent that it triggers an
intervention. Computed tomographic scanning in patients with
closed head trauma may well select a population at greater risk
but does not confer a higher mortality because of the diagnos-
tic procedure itself. 2) Unexplained clinical factors that prompt
clinicians to perform RHC may contribute to the risk of
mortality and increased resource consumption. The decision to
perform RHC is itself a marker that identifies severely ill
patients. Although Connors et al. (1) attempted to eliminate
what they term treatment selection bias, the Committee cannot
conceive of any method, with the possible exception of ran-
domization, by which such selection bias might be eliminated.
Moreover, the computation of the propensity score did not
include a measure of responses to therapy before the perfor-
mance of RHC. 3) The effect of unmeasured confounders was
miscalculated, thus overstating the statistical impact required
for a variable to overcome the increased mortality. 4) Patients
analyzed by Connors et al. (1) may not be characteristic of
patients undergoing RHC. Eighty-four percent had either
acute respiratory failure or multiorgan failure, neither of which
is a specific diagnosis or entity that has a specific treatment and
both of which are associated with high mortality.
None of these criticisms vitiates the possibility that there
are adverse effects of RHC; however, detailed examination of
the data does not provide justification for a moratorium on
RHC. The Expert Consensus Committee is concerned that
multicenter randomized studies are unlikely to resolve the
issues raised by Connors et al. (1) because of the difficulty of
standardizing protocols sufficiently to control effects of thera-
peutic interventions and to accommodate the very large num-
ber of patients that would have to be enrolled.
Indications and recommendations for use of bedside RHC.
For specific recommendations, see Table 1.
Heart failure. RHC is useful for distinguishing between a
cardiogenic and a noncardiogenic (hypovolemic, distributive)
mechanism in patients with shock and between a hemodynamic
and a permeability mechanism in patients with pulmonary
edema. In these settings, the accuracy of clinical assessment of
the presence of left heart failure is limited. Accuracy in
distinguishing between cardiogenic and noncardiogenic shock
and between hemodynamic and permeability pulmonary
edema is critical because the management strategies for these
conditions are quite distinct. The information provided by
RHC often results in a change in therapy. In some patients
with shock, a therapeutic trial of volume infusion may be
indicated; in others, such empiric therapy may be associated
with substantial risk. Similarly, in some patients with dyspnea
or pulmonary edema, or both, a trial of diuretic or vasodilator
therapy, or both, may be attempted without previous RHC; in
others, a strategy that would reduce preload may have delete-
rious consequences. RHC is warranted when these initial
strategies are contraindicated or fail or when there are coex-
isting manifestations of “forward” and “backward” heart fail-
ure. Similarly, RHC is indicated to determine the hemody-
namic contribution to respiratory failure in complex patients
with concurrent pulmonary and cardiac disease. RHC may be
useful for efficiently titrating the dosages of diuretic, vasodila-
tor, inotropic and pressor medications in patients with shock or
severe decompensated heart failure, or both. In contrast, RHC
is not warranted for the routine management of pulmonary
edema, even if endotracheal intubation and mechanical venti-
lation have been necessary.
RHC is helpful in the management of patients with cardiac
disease and failure who are undergoing noncardiac surgery,
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Table 1. Recommendations for Use of Bedside Right Heart Catheterization*
Conditions In Which There Is General Agreement That
RHC is Warranted
Conditions in Which Reasonable Differences of
Opinion Exist Regarding RHC Conditions in Which RHC Is Not Warranted
Heart Failure
1. Differentiation between hemodynamic and
permeability pulmonary edema or dyspnea (or
determination of contribution of left heart failure to
respiratory insufficiency in patients with concurrent
cardiac and pulmonary disease) when a trial of
diuretic and/or vasodilator therapy has failed or is
associated with high risk
2. Differentiation between cardiogenic and
noncardiogenic shock when a trial of intravascular
volume expansion has failed or is associated with
high risk; guidance of pharmacologic and/or
mechanical support
3. Guidance of therapy in patients with concomitant
manifestations of “forward” (hypotension, oliguria,
and/or azotemia) and “backward” (dyspnea and/or
hypoxemia) heart failure
4. Determination of whether pericardial tamponade is
present when clinical assessment is inconclusive and
echocardiography is unavailable, technically
inadequate or nondiagnostic
5. Guidance of perioperative management in selected
patients with decompensated heart failure undergoing
intermediate or high risk (3) noncardiac surgery
6. Detection of presence of pulmonary vasoconstriction
and determination of its reversibility in patients being
considered for heart transplantation
1. Differentiation between hemodynamic and
permeability pulmonary edema or dyspnea (or
determination of the contribution of left heart
failure to respiratory insufficiency in patients with
concurrent cardiac and pulmonary disease) when a
trial of diuretic and/or vasodilator therapy is
associated with low or intermediate risk
2. Differentiation between cardiogenic and
noncardiogenic shock when a trial of intravascular
volume expansion is associated with intermediate
risk
3. Facilitation of titration of diuretic, vasodilator and
inotropic therapy in patients with severe heart
failure
4. Guidance of perioperative management in patients
with compensated heart failure undergoing
intermediate or high risk (3) noncardiac surgery
1. Routine management of pulmonary edema,
even if endotracheal intubation and
mechanical ventilation have been necessary
2. Differentiation between cardiogenic and
noncardiogenic shock before a trial of
intravascular volume expansion, when such
a trial is associated with low risk
3. Institution or titration of diuretic and/or
vasodilator therapy in patients with mild or
moderate heart failure
4. Marked hemodynamic instability in patients
in whom pericardial tamponade is certain
or probable by clinical and/or
echocardiographic criteria and RHC would
delay treatment
5. Guidance of perioperative management in
patients with compensated heart failure
undergoing low risk (3) noncardiac surgery
Acute Myocardial Infarction
1. Differentiation between cardiogenic and hypovolemic
shock when initial therapy with intravascular volume
expansion and low doses of inotropic drugs has failed
2. Guidance of management of cardiogenic shock with
pharmacologic and/or mechanical support in patients
with and without coronary reperfusion therapy
3. Short-term guidance of pharmacologic and/or
mechanical management of acute mitral regurgitation
(with or without disruption of the mitral valve)
before surgical correction
4. Establishment of severity of left to right shunting and
short-term guidance of pharmacologic and/or
mechanical management of ventricular septal rupture
before surgical correction
5. Guidance of management of right ventricular
infarction with hypotension and/or signs of low
cardiac output not responding to intravascular
volume expansion, low doses of inotropic drugs and/
or restoration of heart rate and atrioventricular
synchrony
6. Guidance of management of acute pulmonary edema
not responding to treatment with diuretic drugs,
nitroglycerin, other vasodilator agents and low doses
of inotropic drugs
1. Guidance of ongoing management of hypotension,
after response to initial therapy with intravascular
volume expansion and/or low doses of inotropic
drugs
2. Short-term guidance of pharmacologic and/or
mechanical management of acute mitral
regurgitation if operation is delayed or not
contemplated
3. Establishment of severity of left to right shunting
and short-term guidance of pharmacologic and/or
mechanical management of ventricular septal
rupture if operation is delayed or not
contemplated
4. Guidance of management of right ventricular
infarction, after correction of hypotension and/or
signs of low cardiac output by intravascular
volume expansion, low doses of inotropic drugs
and/or restoration of heart rate and
atrioventricular synchrony
5. Guidance of management of acute pulmonary
edema with vasodilators and/or inotropic drugs,
after initial treatment with diuretic drugs and
nitroglycerin has failed
6. Confirmation of diagnosis of pericardial
tamponade subsequent to subacute myocardial
rupture when clinical and echocardiographic
assessments are inconclusive
1. Guidance of management of postinfarction
angina
2. Guidance of ongoing management of
pulmonary edema responding promptly to
treatment with diuretic drugs and
nitroglycerin
3. Pericardial tamponade with marked
hemodynamic instability, when the
diagnosis is certain or likely by clinical and/
or echocardiographic criteria and RHC
would delay treatment
(Continued)
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particularly patients with decompensated heart failure under-
going intermediate or high risk operation. RHC aids in risk
stratification of patients who are considered for heart trans-
plantation. Patients with substantial fixed elevation of pulmo-
nary vascular resistance have a poor prognosis; patients with
reversible pulmonary vasoconstriction have a more favorable
outcome. Preoperative RHC identifies patients with high
pulmonary vascular resistance and determines its reversibility
in response to vasodilator agents.
Pericardial tamponade constitutes a special case of the
diagnosis and management of heart failure. Tamponade is
suspected on clinical grounds and is best confirmed by echo-
cardiography. RHC is warranted when clinical and echocar-
diographic findings are equivocal. In hemodynamically unsta-
ble patients with suspected pericardial tamponade, timely
therapy should not be delayed by the performance of RHC.
Acute myocardial infarction. The use of RHC in acute
myocardial infarction with hemodynamic instability depends
on the underlying cause and the course of hemodynamic
compromise. In patients with either transient hypotension or
hypotension that responds promptly to intravascular volume
expansion and/or low doses of inotropic drugs, RHC is not
required. If patients do not improve rapidly, RHC is warranted
to distinguish cardiogenic from other forms of shock and to
guide the assessment of the short-term response to pharmaco-
logic agents and mechanical support (intraaortic balloon
pumping). Similarly, transient hypotension and clinical find-
ings of low cardiac output in the setting or right ventricular
infarction can often be managed without RHC, using cautious
volume loading, small doses of inotropic drugs and, if required,
temporary pacing. RHC is warranted when hemodynamic
compromise persists despite initial therapy. Careful monitor-
ing of cardiac output is important because ventricular interac-
tion and pericardial constraint observed in right ventricular
infarction alter diastolic properties of the left ventricle such
that pulmonary artery occlusive pressure (PAOP) is not a
reliable indicator of left ventricular preload.
In the setting of hemodynamic instability caused by acute
mechanical complications after acute myocardial infarction,
echocardiography with Doppler imaging is the primary proce-
dure for the diagnosis. Acute mitral regurgitation with or
without valve disruption, ventricular septal rupture and peri-
cardial effusion or tamponade can be diagnosed rapidly by this
modality. The main indications for RHC in these settings
relate to short-term hemodynamic monitoring of preoperative
and postoperative pharmacologic and mechanical support.
RHC is helpful for monitoring the effect of therapeutic inter-
ventions on the magnitude of shunting through the ventricular
septal defect.
The use of RHC for the guidance of pharmacologic therapy
in patients with heart failure or pulmonary edema (including
those requiring mechanical ventilation), and for prolonged
monitoring of patients with persistent hemodynamic instability
who are not considered for coronary revascularization or
Table 1. (continued)
Conditions In Which There Is General Agreement That
RHC is Warranted
Conditions in Which Reasonable Differences of
Opinion Exist Regarding RHC Conditions in Which RHC Is Not Warranted
Perioperative Use in Cardiac Surgery
1. Differentiation between causes of low cardiac output
(hypovolemia vs. ventricular dysfunction), when
clinical and/or echocardiographic assessment is
inconclusive
2. Differentiation between right and left ventricular
dysfunction and pericardial tamponade, when clinical
and/or echocardiographic assessment is inconclusive
3. Guidance of management of severe low cardiac
output syndrome
4. Diagnosis and guidance of management of
pulmonary hypertension in patients with systemic
hypotension and evidence of inadequate organ
perfusion
1. Guidance of inotropic and/or vasopressor therapy,
after patients with significant cardiac dysfunction
have achieved hemodynamic stability
2. Guidance of management of hypotension and
evidence of inadequate organ perfusion when a
therapeutic trial of intravascular volume expansion
and/or vasoactive agents is associated with
moderate risk
1. Routine management of uncomplicated
cardiac surgical patients with good
ventricular function and hemodynamic
stability
2. Initial management of postoperative
hypotension when a therapeutic trial of
volume expansion and/or vasoactive agents
is associated with low risk
Primary Pulmonary Hypertension
1. Exclusion of postcapillary (elevated PAOP) causes of
pulmonary hypertension
1. Evaluation of long-term efficacy of vasodilator
therapy, particularly prostacyclin
None
2. Establishment of diagnosis and assessment of severity
of precapillary (normal PAOP) pulmonary
hypertension
2. Exclusion of significant left to right or right to left
intracardiac shunt
3. Selection and establishment of safety and efficacy of
long-term vasodilator therapy based on acute
hemodynamic response
4. Assessment of hemodynamic variables before lung
transplantation
*Relative and absolute contraindications, see Main document below.
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surgical repair of structural complications, represent interme-
diate indications for which considerable disagreement exists.
Perioperative use in cardiac surgery. Patients undergoing
cardiac surgery may develop disturbances of perfusion that can
be life-threatening and/or place the function of vital organs at
risk. Identification of the underlying hemodynamic derange-
ments determines therapeutic strategy. RHC facilitates both
the diagnosis and management of low cardiac output states
that may not always be adequately assessed by clinical markers
of perfusion after cardiac surgery. Identification of abnormal-
ities of cardiac output as well as right and left ventricular
afterload or preload is particularly important to guide phar-
macologic and other therapy aimed at optimizing perfusion.
Finally, cardiac surgical techniques involving cardiopulmonary
bypass may result in the accumulation of extravascular lung
water, and RHC often serves as a useful guide for evaluating
the effects of fluid management on global variables of perfu-
sion after cardiac surgery.
Available data do not support the routine use of RHC in
the perioperative period in the hemodynamically stable patient
with good ventricular function. RHC is useful in patients
undergoing cardiac surgery with previous evidence of ventric-
ular dysfunction of any cause, complex coronary artery disease
or valvular disease (especially when it is associated with
significant coronary artery disease or pulmonary hypertension)
and in patients requiring repeat cardiac surgery.
In the postoperative period, RHC is warranted for differ-
entiation among causes of low cardiac output when clinical and
echocardiographic evaluations are inconclusive or therapeutic
trials of intravascular volume expansion and vasoactive agents
have failed or are associated with high risk. However, reason-
able differences of opinion exist as to whether RHC should be
used for guidance of inotropic and/or vasopressor therapy after
hemodynamic stability has been achieved in patients with
significant cardiac dysfunction.
Primary pulmonary hypertension. RHC is warranted for
establishing the diagnosis of precapillary (normal PAOP)
pulmonary hypertension and to accurately assess its severity.
Although echocardiography/Doppler imaging can be used to
estimate pulmonary artery systolic pressure, measurement of
PAOP, which is essential to distinguish between postcapillary
and precapillary pulmonary hypertension and to determine
pulmonary vascular resistance, cannot presently be accom-
plished without RHC. RHC is warranted before institution of
long-term pharmacologic therapy of primary pulmonary hyper-
tension, in particular when calcium channel blocking agents
are used, to evaluate the hemodynamic response to vasodila-
tors. The pattern of the acute hemodynamic response has been
shown to correlate with long-term prognosis. Adverse hemo-
dynamic responses, such as a reduction in cardiac output or
systemic arterial pressure, or an increase in right atrial pres-
sure, regarded as contraindications to long-term vasodilator
therapy, can only be determined by hemodynamic monitoring.
There is considerable difference of opinion as to whether RHC
should be used for evaluation of long-term efficacy of vasodi-
lator therapy.
Complications. Complications related to RHC are associ-
ated with the establishment of central venous access, the
catheterization procedure itself and catheter residence.
Adverse events related to central venous cannulation in-
clude arterial puncture, bleeding at the site of insertion, nerve
injury, pneumothorax and air embolism. The primary compli-
cations related to the RHC procedure itself are arrhythmias,
which are usually clinically insignificant. Sustained ventricular
arrhythmias are uncommon and occur primarily in patients
with myocardial ischemia or infarction or preexisting ventric-
ular arrhythmias. The most serious complications of RHC are
related to catheter residence. They include pulmonary artery
rupture, thrombophlebitis, venous or intracardiac thrombus
formation, pulmonary infarction and endocarditis. The risk of
thrombotic and infectious complications increases significantly
when the catheter remains in place .3 to 4 days.
Alternative or complementary procedures. Echocardiogra-
phy with Doppler imaging is the most important alternative or
complementary procedure to RHC in the critically ill cardiac
patient. It elucidates the likely mechanism of hypotension and
shock, aiding the distinction between cardiogenic and noncar-
diogenic shock. Echocardiography/Doppler imaging has a pri-
mary role in the diagnosis of mechanical complications after
acute myocardial infarction, including acute mitral regurgita-
tion with and without valve disruption, ventricular septal defect
and ventricular free wall rupture. Transesophageal echocardi-
ography (TEE) is superior to transthoracic echocardiography
(TTE) in certain patients, facilitating data acquisition and
enhancing diagnostic information. Estimation of left ventricu-
lar filling pressure and stroke volume for hemodynamic mon-
itoring has not yet been validated for widespread clinical use as
an alternative to RHC. These techniques remain the subject of
continued clinical investigation. TEE plays an important role
in the perioperative period for evaluation of left ventricular
function and results of valve repair. It is of particular value
in the patient with hypotension and low cardiac output
during separation from cardiopulmonary bypass. A variety
of promising developments, including miniaturized probes
and techniques for real time on-line monitoring of ventric-
ular volumes, ejection fraction and compliance, are under
clinical investigation.
Proposals for randomized trials. The Expert Consensus
Committee considered carefully the role of future research for
the evaluation of the safety and efficacy of RHC in patients
with cardiac disease. It identified two areas, namely heart
failure and cardiac surgery, in which RHC is frequently used
and randomized trials may be considered. The Committee
came to the following conclusions:
1. Randomized clinical trials in patients with heart failure
are ethical in those subjects (such as patients with severe heart
failure who require titration of diuretic, vasodilator and ino-
tropic therapy) for which reasonable differences of opinion
exist regarding the indication for RHC. For considerations of
sample size and power, end points other than mortality would
be necessary and should include morbidity, length of intensive
care unit (ICU) and total hospital stay and cost. For the benefit
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of RHC to be assessed, it must be deployed in clinical
conditions for which beneficial treatment is available.
2. The efficacy and safety of RHC in low risk patients
undergoing cardiac surgery could be established by a clinical
trial, but such a trial would be difficult to perform. RHC would
be expected to have minimal effect on mortality and morbidity,
and the required sample size would be very large. In the
absence of sufficient power for examining a clinical end point,
a cost-effectiveness study would not be feasible. In the case of
an equivalent outcome whether or not RHC was used, a pure
cost study (cost minimization study) would be possible. A
clinical trial in high risk patients undergoing cardiac surgery is
more likely to be revealing because the incidence of end points
will be higher, and the potential of RHC to affect outcome
would appear to be greater than in a trial in low risk patients.
However, the Expert Consensus Committee is concerned that
such a trial would be difficult to perform because of unwilling-
ness of physicians to randomize patients.
Conclusions. The Expert Consensus Committee was con-
vened to formulate recommendations for the use of bedside
RHC in patients with known or suspected cardiac disease.
Because few data are available from well controlled clinical
trials, the recommendations are based primarily on inferences
from published reports and expert opinion. The role of RHC is
currently in transition because of the availability of noninvasive
diagnostic techniques, in particular, echocardiography with
Doppler, which in some cases complement and in others are
alternatives to RHC. RHC has a primary role in the
management of heart failure in certain patients in whom the
diagnosis of heart failure is uncertain, heart failure is of
sufficient severity to require intensive pharmacologic man-
agement or heart transplantation is contemplated. In pa-
tients with acute myocardial infarction, echocardiography
has a primary role in the diagnosis of mechanical complica-
tions, and RHC is helpful in certain instances for assessment
of the severity of hemodynamic compromise and the re-
sponse to therapy. The Committee does not recommend the
routine use of RHC in patients undergoing uncomplicated
cardiac surgery who have good ventricular function and
hemodynamic stability.
The Committee is not optimistic about the feasibility of
randomized clinical trials to establish the safety and efficacy of
RHC, with the possible exception of a trial in patients with
refractory decompensated heart failure. The Committee ques-
tions whether major resources should be devoted to reevalua-
tion of the role of RHC or whether such resources would be
better directed toward future development and evaluation of
semi-invasive and noninvasive diagnostic techniques.
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Present Use of Bedside Right Heart Catheterization in Patients With
Cardiac Disease
Preamble
Method of topic selection. This Expert Consensus Docu-
ment on right heart catheterization (RHC) at the bedside was
developed at the request of the Technology and Practice
Executive Committee of the American College of Cardiology
(ACC) in response to a major increase in interest in this area.
The Expert Consensus Document is intended to inform prac-
titioners, payers and other interested parties of the opinion of
the ACC concerning evolving areas of clinical practice and/or
technologies that are widely available or are new to the
practice community. Topics chosen for coverage by Expert
Consensus Documents are so designated because the evidence
base and experience with the technology or clinical practice are
not sufficiently well developed to be evaluated by the formal
ACC/American Heart Association (AHA) practice guidelines
process. Thus, the reader should view the Expert Consensus
Document as the best attempt of the ACC to inform and guide
clinical practice in areas where rigorous evidence is not yet
available. Some topics covered by Expert Consensus Docu-
ments will be addressed subsequently by the ACC/AHA prac-
tice Guidelines process.
Introduction
The introduction in the early 1970s of bedside RHC (4) led
to profound changes in the practice of cardiology and fostered
major advances in the diagnosis and treatment of critically ill
patients with cardiac disease. However, new cardiac diagnostic
and treatment strategies that have evolved in the past two
decades have placed RHC in a different perspective. Improved
imaging modalities, in particular, TTE and TEE, provide
important information regarding cardiac function and struc-
ture frequently in lieu of RHC. The increased use of cardiac
catheterization, including RHC, and mechanical coronary re-
vascularization in patients with acute ischemic syndromes has
decreased the need for bedside RHC. New pharmacologic
agents, such as thrombolytic agents and antiplatelet drugs,
present relative contraindications to RHC and thus favor
noninvasive assessment over RHC.
A recent case-control study (1) reported excess mortality
and length of stay in a diverse group of cardiac and noncardiac
patients who had undergone RHC, and an accompanying
editorial called for a moratorium on RHC (2). In response to
these publications, the Technology and Practice Executive
Committee (TPEC) appointed this Expert Consensus Commit-
tee and charged it with two related tasks: 1) to provide peer
comments on the study by Connors et al. (1); and 2) to reassess
the role of RHC in patients with cardiac disease, providing
recommendations for current use and future research. The Con-
sensus Committee included a variety of experts, encompassing
invasive and noninvasive cardiology, critical care medicine, car-
diac anesthesia, epidemiology and biostatistics. The recommen-
dations of the Committee are based on published data and, in the
absence of conclusive data, on a consensus among its members. In
accordance with ACC policy, the recommendations are prefaced
by background information regarding the various clinical situa-
tions considered by the Committee.
Several societies have established guidelines for the use of
RHC, including recommendations for quality control (5–10).
Each of the guidelines recognized the paucity of objective
information, particularly outcome data, derived from random-
ized trials. Although prospective, randomized trials do form a
basis for clinical practice, any valid study of RHC requires a
definable measure of competency in both the acquisition and
interpretation of data from RHC. There is considerable vari-
ation among physicians (11,12) and nurses (13) in the quality
of acquisition and interpretation of the data obtained by RHC
and subsequent integration into therapeutic strategies. There
is also considerable variation in the experience of physicians
caring for critically ill patients with cardiac disease and in the
perceived need for RHC. These differences create certain
difficulties regarding recommendations for the use of RHC as
well as for the planning of multicenter trials. Programs for
education of physicians and other health professionals in the
use of RHC are of considerable importance.
The design of future research on the role of bedside RHC
should consider alternative monitoring options that are less
invasive. Echocardiographic acquisition of anatomic and
physiologic data (14), Doppler estimation of cardiac pres-
sures (15,16) and continuous TEE in the critical care setting
(17,18) are presently under intense clinical investigation and
may evolve to promising tools for the provision of compre-
hensive information. Careful consideration is required to
determine whether resources should be directed mainly
toward the reevaluation of bedside RHC or should be
directed preferentially toward the development and investi-
gation of newer noninvasive or less invasive monitoring
modalities.
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Evaluation of a Case-Control Study of RHC
by Connors Et Al.
The recent study by Connors et al. (1) concluded that after
adjustment for treatment selection bias, RHC was associated
with increased mortality and increased utilization of resources.
An accompanying editorial proposed a moratorium on RHC
(2). The Expert Consensus Committee addressed the following
issues:
The right heart catheter is a monitoring device and as such
is a diagnostic rather than a treatment modality. In life-
threatening settings, the overriding benefit of a diagnostic or
monitoring device is the intervention that it triggers. In this
respect, the adverse impact of a diagnostic intervention, in-
cluding the potential morbidity and, in rare instances, mortality
stemming from the use of the device itself, cannot be evaluated
except to the extent that therapeutic interventions are con-
trolled. For example, request of computed tomographic scans
for patients with closed head trauma may well select a popu-
lation at greater risk, but it does not imply a higher mortality
for them because they undergo risks of transport and position-
ing for imaging. The objective documentation in the report of
Connors et al. (1) therefore does not allow for clear-cut
separation of any adverse effect of the diagnostic intervention,
represented by RHC, and the severity of the disorder together
with the effects of a diversity of therapeutic interventions. The
observations reported by Connors et al. (1) are alternatively
explained by selection of more serious disorders and unsuc-
cessful treatment strategies (19).
Unexplained clinical factors that prompt clinicians to
perform RHC may contribute significantly to the risk of
mortality and increased resource consumption. The decision
to perform RHC is itself a marker that identifies severely ill
patients. We recognize the attempts of Connors et al. (1) to
eliminate what they term treatment selection bias. Yet, if this
diagnostic intervention selects patients for whom there is
greater likelihood of morbidity and mortality, we cannot
conceive of any method, with the possible exception of ran-
domization, by which such selection might be eliminated.
Because the study by Connors et al. (1) was not randomized,
comparisons between patients who did and those who did not
receive RHC depended on a propensity score intended to
predict whether RHC would be utilized. Among the clinical
variables included in the computation of the propensity, re-
sponses to therapy were excluded. To emphasize this point, the
clinical features of two patients presenting with pulmonary
edema might be considered. The patient responding to initial
therapy with diuretic drugs would probably not become a
candidate for RHC, whereas the patient in whom more
extensive pharmacologic therapy failed would be more likely to
undergo RHC, thus inevitably facing a higher mortality risk
(20,21). Yet the propensity score as presented would fail to
distinguish between these patients.
The effect of unmeasured confounders was miscalculated.
Connors et al. (1) estimated that to account for the 20%
increased risk of death in the RHC group, a missing covariate
would have to increase the risk of death and the probability of
RHC threefold. To change the 20% increased risk to a 20%
decreased risk, a missing covariate would have to increase the
risk of death and the probability of RHC sixfold. In calculating
these estimates, Connors et al. (1) have used their estimated
odds ratios as if they were probability ratios. An increase in the
probability of RHC increases the odds ratio more than it
increases the probability ratio. Thus, the effect of unmeasured
confounders needed to reduce the observed association was
overestimated. The effect that would change the observed 20%
increased risk in the RHC groups to no increased risk is
actually only a twofold increase in propensity and mortality. A
threefold increase in the probability of RHC and the risk of
death would change the relative risk to a 20% decrease in risk
(22). Thus, an unmeasured confounder with only a moderately
independent effect could account completely for the observed
association.
The development of the propensity score and the sensitivity
analysis apply primarily to patients with acute respiratory and
multiple organ system failure. Patients with acute respiratory
and multiple organ system failure account for 80% of the
patients analyzed by Connors et al. (1). No patients with
cardiac diagnoses, possibly the largest group undergoing RHC
in clinical practice, were included in these groups. In the 11%
of patients who had congestive heart failure (CHF), the
relative odds of death was 1.02, indicating neither harm nor
benefit. The addition of an unmeasured covariate with only a
modest effect on propensity and mortality could change the
estimated odds in this group to significant benefit for RHC.
Possible benefit for other patient subgroups included in the
largest groups may also have been overlooked.
None of these specific criticisms vitiates the possibility that
there are adverse effects of RHC. However, a detailed exam-
ination of the data does not provide justification for a mora-
torium on RHC. More objective information is needed before
any such drastic action can be recommended (9,11). The
Expert Consensus Committee is concerned that multicenter,
randomized studies are unlikely to resolve these issues because
of the difficulty of standardizing protocols sufficiently to con-
trol effects of therapeutic interventions and to accommodate
the very large number of patients that would have to be
enrolled. Because critically ill patients are a heterogeneous
group, subgroups would have to be defined. The challenge of
achieving adequate statistical power in such subgroups is likely
to be very great. Furthermore and perhaps more fundamen-
tally, the use of RHC is not in equipoise (23,24).
Although the Committee cautions against complacency, it
believes that it is crucial, in the absence of scientifically secured
data, to maintain objectivity and secure appropriate consensus
with respect to the questions posed by Connors et al. (1).
Acquisition and Interpretation of Data
Safe and effective use of RHC is predicated on careful
catheter placement, attention to measurement techniques and
thoughtful interpretation of the data. Skillful placement of the
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catheter and interpretation of data will optimize the benefit/
risk ratio of this modality.
RHC must be performed with strict sterile technique. If the
catheter is placed through a protective sleeve with meticulous
attention to maintaining its sterility, the catheter may be
advanced, if necessary, within 24 h of placement. After 24 h,
the catheter should preferably not be advanced. To minimize
the risk of infection, the catheter should be left in place for
only as long as it provides information essential for patient
management. In general, this period should not exceed 3 days;
when catheters are left in place for .3 days, justification
should be provided. The strategy of routine replacement of
catheters over guide wires or through repeat venipuncture has
not been demonstrated to reduce the risk of infection (25).
When the catheter tip is in the pulmonary artery, the
balloon should be inflated slowly, using tactile assessment of
balloon pressure and intravascular pressure waveform moni-
toring; this will minimize the risk of pulmonary artery rupture
and associated hemorrhage. If concordance between pulmo-
nary artery occlusive pressure (PAOP) and pulmonary artery
diastolic pressure is established, frequent measurements of the
former may not be necessary.
In most cases, RHC through the internal jugular, subclavian
or antecubital approach may be performed at the bedside,
without fluoroscopy. Fluoroscopic guidance should be considered
in the presence of a temporary or recently placed permanent
pacemaker or implantable cardioverter-defibrillator; right atrial
and/or ventricular dilation, severe tricuspid regurgitation; or
left bundle branch block. In the latter instance, fluoroscopy offers
the advantages of minimizing catheter manipulation in the right
heart, lessening the likelihood of concurrent right bundle branch
block leading to complete block, and of facilitating the rapid
positioning of a temporary pacemaker, should complete heart
block nevertheless occur. Alternatively, the availability of
standby transcutaneous pacing allows for RHC in the presence
of left bundle branch block without the use of fluoroscopy.
RHC allows for measurement of 1) central venous or right
atrial pressure; 2) pulmonary artery systolic, diastolic and
mean pressures; 3) PAOP or “wedge” pressure; 4) thermodi-
lution cardiac output; and 5) oxygen saturation.
Current practice is to measure right heart pressures relative
to zero pressure defined at the midaxillary line. It has been
suggested that pressure is more correctly referenced from the
upper border of the left ventricle (26) and that zero reference
pressure is best estimated in a plane 5 cm below the sternal
angle (27). Meticulous flushing of catheters, transducer devices
and tubing to remove blood and air reduces the risk or errors
in measurement caused by damping of pressure tracings.
According to principles of cardiopulmonary physiology,
current ICU practice is to record PAOP and other pressures at
end-exhalation. This practice differs from that of cardiac
catheterization laboratories (and in a large body of published
reports on which much of our understanding of the clinical
significance of pressure measurements is based), which is to
record mean pressures averaged throughout the respiratory
cycle. These disparate practices create a discrepancy between
pressures measured in the ICU and those measured in the
cardiac catheterization laboratory. In a patient breathing with-
out the aid of positive pressure, end-exhalatory pressure is
higher than mean pressure; in a patient receiving positive
pressure ventilation, end-exhalatory pressure is lower than
mean pressure. Until the practices of ICUs and cardiac
catheterization laboratories converge, the clinician must be
aware of the differences in measurement technique and must
interpret the data accordingly.
For the PAOP to reflect left atrial pressure accurately,
there must be a patent fluid column between the catheter tip
and the left atrium. If alveolar pressure exceeds hydrostatic
pressure in the pulmonary capillaries, they collapse; in this
instance, the measured pressure may be grossly misleading.
Thus, the pressure recorded when a pulmonary artery branch
is occluded by a balloon (PAOP) reflects pulmonary venous
(and thus left atrial) pressure only when pulmonary venous
(Pv) and pulmonary artery (Pa) pressures exceed pulmonary
alveolar (PA) pressure (i.e., Pa . Pv . PA, defined as West
zone 3 [28]). In other regions of the lung (West zones 1 and 2),
balloon inflation results in measurement of alveolar pressure
(29). Fortunately, with the patient supine, most of the lung
consists of zone 3 units (30).
In the presence of positive end-expiratory pressure (PEEP),
alveolar pressure is higher, so that less of the lung consists of
zone 3 units, and the likelihood of catheter placement in zones
1 or 2 increases. Inaccurate estimation of left atrial pressure is
likely when the catheter is above the level of the left atrium
(31) or when the catheter is at the level of the left atrium but
the left atrial pressure is low. In one study (32), 43% of
catheters placed through the internal jugular approach lodged
at or above the level of the left atrium, yielding inaccurate
assessment of left atrial pressure in the presence of PEEP.
Even in the absence of an increase in alveolar pressure to a
level that exceeds pulmonary venous pressure, the use of PEEP
may affect the measurement of intravascular pressures because
the positive airway pressure may be transmitted to the central
vessels. The problem is particularly significant when .10 cm
H2O of PEEP is used (33,34). Although a formula for correc-
tion has been offered (35), the extent to which an increase in
airway pressure is transmitted to the pulmonary vasculature is
variable and not accurately predictable.
Although PAOP is often used as an estimate of both
pulmonary capillary pressure, the driving force for shifting
fluid from pulmonary capillaries into the interstitium and
alveoli, and left ventricular diastolic pressure, it is an imperfect
measure of both. Although the pulmonary capillary pressure
exceeds PAOP by only a few mm Hg in the normal lung, it may
exceed PAOP by 10 to 15 mm Hg in sepsis and other inflamma-
tory disorders, resulting in pulmonary edema despite an “accept-
able” PAOP (36). PAOP reflects left atrial pressure, which is in
turn indicative of left ventricular diastolic pressure only in the
absence of mitral stenosis or more than mild mitral regurgitation.
Furthermore, the relation between left ventricular pressure and
volume in diastole depends critically on ventricular compliance,
which is often abnormal in critically ill patients.
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The concept of an “optimal” PAOP for maximizing left
ventricular output was introduced along with the pulmonary
artery catheter. Traditional values for “optimal” PAOP, typi-
cally 14 to 18 mm Hg, were based on early data from patients
with acute myocardial infarction (37). Since then there have
been changes both in the therapy of myocardial infarction and
in the techniques for measuring PAOP. Despite these changes,
the concept of optimal PAOP has remained and has been
extrapolated to other patient groups. However, it has been
shown (38) that effective vasodilator treatment of patients with
heart failure results in higher output and lower PAOP, with no
“lower limit” or optimal PAOP. Optimal PAOP varies greatly
among patients and requires an empiric approach that assesses
clinical status and cardiac output at various filling pressures in
an individual patient. In assessing the effects of therapeutic
interventions, directional changes in PAOP may be more
useful than absolute values of PAOP.
Pressures and thermodilution cardiac output measurements
should be interpreted, when appropriate, together with mea-
surements of pulmonary artery oxygen saturation and arterio-
venous oxygen difference. Thermodilution cardiac output may
be inaccurate in the presence of arrhythmias, tricuspid regur-
gitation (39) and intracardiac shunting. Data obtained from
RHC should be interpreted in the context of clinical assess-
ment, taking into account weight, input/output tallies, mental
status, skin temperature, lung examination, urine output, blood
urea nitrogen, creatinine, arterial PO2 and pH and chest
radiographic and, when appropriate, echocardiographic findings.
Technology of right heart catheters. The routinely used
balloon flotation catheters have four lumens, including two for
transmission of pressure signals from the pulmonary artery and
the right atrium, one for balloon inflation and one for a
thermostat located near the catheter tip. Multipurpose elec-
trode catheters incorporate atrial and ventricular electrodes
for recording of intraatrial and intraventricular electrocardio-
grams, facilitating the diagnosis of complex arrhythmias (40)
and, in rare instances, temporary pacing. Newer catheters have
a fifth lumen containing fiberoptic bundles for measurement of
mixed venous oxygen saturation. Balloon flotation catheters
with the additional capability of measuring right ventricular
stroke volume, end-systolic and end-diastolic volumes and
ejection fraction have been introduced (41). Continuous de-
termination of cardiac output is feasible by the thermodilution
principle with the use of a specially designed cardiac output
computer without requiring delivery of indicator solution (42).
Alternatively, Doppler techniques may be used for determina-
tion of continuous cardiac output (43). Heparin-bond cathe-
ters designed to decrease catheter thrombosis and catheters
impregnated with antiseptic agents are also available.
Method of Data Collection
A MEDLINE search of published reports in English from
1966 to 1997 was performed. Swan-Ganz catheterization or
RHC in patients was cross-checked with the following terms:
unstable angina, myocardial infarction, pulmonary edema,
cardiogenic shock, flail mitral leaflet, mitral valve papillary
muscle rupture, ventricular septal rupture, pericardium, peri-
cardial effusion, pericardial tamponade, heart failure, decom-
pensated heart failure, cardiac surgery, coronary artery bypass
graft surgery (CABG), heart transplantation, pulmonary hy-
pertension, inotropic agents, vasodilator agents, vasoconstric-
tor agents and intraaortic balloon pumping (counterpulsation).
The document took in account this review of the published
reports. In addition, members of the Expert Consensus Com-
mittee utilized published reports at their own discretion,
according to their particular fields of interest and expertise.
Guidelines related to cardiology, cardiac surgery, cardiac an-
esthesiology and critical care medicine published during the
past decade were reviewed.
Grading of recommendations. The recommendations were
graded according to the guidelines for Expert Consensus
Documents provided by the TPEC of the ACC, as follows:
1. Conditions in which there is general agreement that RHC is
warranted.
2. Conditions in which reasonable differences of opinion exist
regarding RHC.
3. Conditions in which RHC is not warranted.
4. Conditions in which a relative contraindication to RHC exists.
5. Conditions in which an absolute contraindication to RHC
exists.
Indications and Recommendations for Use of
Bedside RHC
Heart Failure
Background. Accurate assessment of hemodynamic status.
In patients with shock, the distinction between a cardiogenic
and a noncardiogenic (hypovolemic, distributive) mechanism is
essential for directing management. In patients with pulmo-
nary edema, the distinction between a hemodynamic and a
permeability mechanism determines therapeutic strategy. In
these settings, a number of studies have suggested that the
accuracy of clinical assessment of the presence of left heart
failure is limited. Clinical assessment is handicapped by the
fact that the radiographic appearance of pulmonary edema is
neither sensitive nor specific for the diagnosis of pulmonary
venous hypertension. In particular, patients with chronic ele-
vation of PAOP may have compensatory mechanisms that
obfuscate physical and radiographic signs of left heart failure.
Thus, in patients with decompensation of chronic heart failure
(as distinct from patients with acute myocardial infarction),
clinical assessment may be insensitive for the detection of
elevated PAOP (44,45). Conversely, the radiographic finding
of pulmonary edema is nonspecific for the diagnosis of left
heart failure (46); there are many causes of permeability
pulmonary edema. Several studies of patients without acute
myocardial infarction carried out in the medical ICU setting
have suggested that clinical assessment of PAOP may be
inaccurate (47,48).
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Accuracy in distinguishing between cardiogenic and non-
cardiogenic shock and between hemodynamic and permeabil-
ity pulmonary edema is critical because the management
strategies for the two conditions are quite distinct. The infor-
mation provided by RHC often results in a change in therapy
(47,48).
Pericardial tamponade. Patients with suspected pericardial
tamponade constitute a special case of the diagnosis of heart
failure. Tamponade is suspected on clinical grounds (tachycar-
dia, pulsus paradoxus and jugular venous distention) and is
best confirmed by echocardiography (pericardial effusion with
Doppler echocardiographic signs of tamponade). In some
cases, echocardiography may be unavailable or technically
suboptimal. The findings of “equalization” of right atrial, right
ventricular diastolic, pulmonary artery diastolic pressures and
PAOP and of absence or blunting of the y descent in the right
atrial tracing by RHC support the diagnosis of pericardial
tamponade. Equalization of pressures may occur in other
conditions, such as right ventricular infarction and pericardial
constriction, and may be absent in pericardial tamponade, for
example, if there is an independent cause of elevation of left
atrial pressure. In selected patients, RHC may be useful for
documenting the hemodynamic response (fall in filling pres-
sures, increase in cardiac output) that accompanies removal of
pericardial fluid and for detecting persistently abnormal hemo-
dynamic variables (elevated right atrial pressure with promi-
nent x and y descents) in patients with effusive–constrictive
pericardial disease (49). In hemodynamically unstable patients
with suspected pericardial tamponade, timely therapy should
not be delayed by the performance of RHC.
Management of severe heart failure. Invasive hemodynamic
measurements may be useful for effectively and efficiently
titrating the dosages of diuretic, vasodilator and inotropic
medications, particularly during acute exacerbations of chronic
heart failure or hemodynamic instability (50). Stevenson et al.
(51) have introduced the concept of “tailored therapy” for
heart failure. In their initial report, 50 patients who were
candidates for urgent heart transplantation underwent RHC.
Nitroprusside infusion and intermittent intravenous furo-
semide were administered in an attempt to achieve a PAOP of
15 to 20 mm Hg and a systemic vascular resistance #1,200
dyneszs/cm5 while maintaining systolic blood pressure
$80 mm Hg. Oral vasodilator agents were subsequently added
as intravenous medications were discontinued. Of the 50
patients, 40 were discharged without transplantation (51). In
152 patients undergoing such tailored therapy, mortality was
predicted by failure of PAOP to improve during therapy (p 5
0.005) (52). The authors acknowledged that it is not known
whether the achievement of low filling pressures improved
survival or merely identified those patients with potential for
survival (52). A study of survivors demonstrated continued
hemodynamic efficacy of therapy after a mean of 8 months of
follow-up (53).
Management of patients with heart failure undergoing noncar-
diac surgery. The special case of management of patients with
heart failure undergoing noncardiac surgery was addressed in
the 1996 report of the ACC/AHA Task Force on Practice
Guidelines (Committee on Perioperative Cardiovascular Eval-
uation for Noncardiac Surgery) (3). The Committee suggested
that “patients with signs and symptoms of heart failure preop-
eratively, who have a very high (35%) postoperative incidence
of heart failure, may benefit from invasive hemodynamic
monitoring.” It recommended that “preoperative preparation
in an intensive care unit may benefit certain high risk patients,
particularly those with decompensated CHF” and those under-
going high risk (emergency, prolonged or certain vascular)
operations. The introduction of TEE has decreased the intra-
operative use of RHC in some institutions. However, the
hemodynamic information obtained from RHC is complemen-
tary to that derived from TEE, and RHC provides serial data
to guide management in the postoperative period, when infor-
mation from TEE is less readily available.
Evaluation of patients for heart transplantation. Evaluation
for heart transplantation constitutes another special case of the
management of patients with heart failure. The outcome of
heart transplantation is poor in patients with substantial fixed
preoperative elevation of pulmonary vascular resistance; such
patients have a high incidence of postoperative right heart
failure (54). Patients with reversible pulmonary vasoconstric-
tion have a more favorable outcome after heart transplantation
(55). Preoperative RHC identifies patients with high pulmo-
nary vascular resistance and determines reversibility in re-
sponse to vasodilator agents, such as oxygen, nitroprusside and
nitric oxide (56). This assessment may be carried out in the
ICU or cardiac catheterization laboratory.
Expert opinion of the Committee. Some guidelines for
RHC in patients with heart failure were provided by the 1995
report of the ACC/AHA Task Force on Practice Guidelines
(Committee on Evaluation and Management of Heart Failure)
(57). In some patients with dyspnea and/or pulmonary edema,
a trial of diuretic and/or vasodilator therapy may be attempted
without previous RHC; in others (e.g., some patients with
normal left ventricular ejection fraction and suspected diastolic
dysfunction), a strategy that would reduce preload may have
deleterious consequences (58). Similarly, in some patients with
shock, a therapeutic trial of volume infusion may be indicated;
in others (especially those with respiratory distress who have
not undergone endotracheal intubation and mechanical venti-
lation), such empiric therapy may also be associated with
substantial risk. Right heart catheterization is warranted when
these initial strategies are contraindicated or fail or when there
are coexisting manifestations of “forward” (low output with
hypotension, oliguria and/or azotemia) and “backward” (pul-
monary venous hypertension with dyspnea and/or hypoxemia)
heart failure. Similarly, RHC is indicated to determine the
hemodynamic contribution to respiratory failure in patients
with concurrent pulmonary and cardiac disease. In contrast,
RHC is not warranted for the routine management of pulmo-
nary edema, even if endotracheal intubation and mechanical
ventilation have been necessary, or for the institution or
titration of diuretic and vasodilator therapy in patients with
mild or moderate heart failure.
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RHC may be helpful to guide inotropic and pressor therapy
in patients with severe decompensated heart failure and car-
diogenic shock, respectively. It is warranted in the special cases
of some patients with suspected pericardial tamponade, pa-
tients with decompensated heart failure undergoing noncar-
diac surgery and patients undergoing evaluation for heart
transplantation. It should not be performed before pericardio-
centesis in patients with hemodynamic instability when the
diagnosis of pericardial tamponade is certain or probable. The
use of RHC to guide diuretic and vasodilator therapy in
patients with heart failure constitutes an intermediate indica-
tion over which there is substantial disagreement. Similarly,
there is disagreement regarding the need for RHC in patients
with compensated heart failure undergoing noncardiac sur-
gery; use of RHC should be reserved for patients undergoing
high risk operations.
Recommendations: Heart Failure
Conditions in which there is general agreement that RHC
is warranted
1. Differentiation between hemodynamic and permeability
pulmonary edema or dyspnea (or determination of the
contribution of left heart failure to respiratory insufficiency
in patients with concurrent cardiac and pulmonary disease)
when a trial of diuretic and/or vasodilator therapy has failed
or is associated with high risk.
2. Differentiation between cardiogenic and noncardiogenic
shock when a trial of intravascular volume expansion has
failed or is associated with high risk; guidance of pharma-
cologic and/or mechanical support.
3. Guidance of therapy in patients with concomitant mani-
festations of “forward” (hypotension, oliguria and/or
azotemia) and “backward” (dyspnea and/or hypoxemia)
heart failure.
4. Determination of whether pericardial tamponade is present
when clinical assessment is inconclusive and echocardiogra-
phy is unavailable, technically inadequate or nondiagnostic.
5. Guidance of perioperative management in selected patients
with decompensated heart failure undergoing intermediate
or high risk (3) noncardiac surgery.
6. Detection of the presence of pulmonary vasoconstriction
and determination of its reversibility in patients being
considered for heart transplantation.
Conditions in which reasonable differences of opinion exist
regarding RHC
1. Differentiation between hemodynamic and permeability
pulmonary edema or dyspnea (or determination of the
contribution of left heart failure to respiratory insufficiency
in patients with concurrent cardiac and pulmonary disease)
when a trial of diuretic and/or vasodilator therapy is asso-
ciated with low or intermediate risk.
2. Differentiation between cardiogenic and noncardiogenic
shock when a trial of intravascular volume expansion is
associated with intermediate risk.
3. Facilitation of titration of diuretic, vasodilator and inotropic
therapy in patients with severe heart failure.
4. Guidance of perioperative management in patients with
compensated heart failure undergoing intermediate or high
risk (3) noncardiac surgery.
Conditions in which RHC is not warranted
1. Routine management of pulmonary edema, even if endo-
tracheal intubation and mechanical ventilation have been
necessary.
2. Differentiation between cardiogenic and noncardiogenic
shock before a trial of intravascular volume expansion,
when such a trial is associated with low risk.
3. Institution or titration of diuretic and/or vasodilator therapy
in patients with mild or moderate heart failure.
4. Marked hemodynamic instability in patients in whom peri-
cardial tamponade is certain or probable by clinical and/or
echocardiographic criteria, and RHC would delay treatment.
5. Guidance of perioperative management in patients with
compensated heart failure undergoing low risk (3) noncar-
diac surgery.
Conditions in which a relative contraindication to RHC
exists
1. Coagulopathy (or anticoagulant therapy that cannot be
temporarily discontinued).
2. Recent implantation of permanent pacemaker or
cardioverter-defibrillator (in which case placement under
fluoroscopic guidance is recommended).
3. Left bundle branch block (see “Acquisition and Interpreta-
tion of Data”).
4. Bioprosthetic tricuspid (or pulmonic) valve.
Conditions in which an absolute contraindication to RHC
exists
1. Right-sided endocarditis.
2. Mechanical tricuspid (or pulmonic) valve prosthesis.
3. Presence of thrombus or tumor in right heart chamber.
4. Terminal illness for which aggressive management is con-
sidered futile.
Acute Myocardial Infarction
Background. The routine use of RHC in uncomplicated
acute myocardial infarction has never been recommended.
Gore et al. (20) and Yarzebski et al. (59) examined the use of
RHC over time in patients with acute myocardial infarction in
Worcester, Massachusetts. They found an increase in the use
of RHC from 1975 to 1984, followed by a progressive decline
until 1990, the last year examined. Even before restrictions
imposed by cost containment, managed care and published
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guidelines, the cardiology community had already reduced the
use of RHC in acute myocardial infarction on the basis of
clinical judgment and experience.
Indications for the use of RHC are related to the diagnosis
and management of specific complications of myocardial in-
farction. These include 1) hypotension, low cardiac output and
cardiogenic shock as a consequence of predominant left ven-
tricular failure; 2) acute mechanical complications (mitral
regurgitation from papillary muscle rupture or ischemia, ven-
tricular septal rupture or ventricular free wall rupture); 3)
complicated right ventricular infarction; and 4) heart failure or
pulmonary edema unresponsive to routine management.
The role of RHC has changed because of the availability of
noninvasive diagnostic techniques, in particular, echocardiog-
raphy. Echocardiography with Doppler imaging is the proce-
dure of choice for the evaluation of left and right ventricular
function and the diagnosis of complications of acute myocar-
dial infarction (see later [“Alternative or Complementary
Procedures”]). The major role of RHC is related to guiding the
management of complications, such as therapy with vasoactive
agents, intraaortic balloon pumping (IABP) and other inter-
ventions. If echocardiography with Doppler imaging is not
available, RHC remains an important modality for the diag-
nosis of complications of myocardial infarction.
Hypotension, low cardiac output state and cardiogenic shock.
RHC is most commonly used in the setting of acute myocardial
infarction to guide the management of low cardiac output,
hypotension and cardiogenic shock. Published guidelines con-
sistently recommend the use of RHC in cardiogenic shock
(5–7,10). Although the diagnosis of shock is dependent on the
presence of hypotension and clinical signs of organ hypoper-
fusion (oliguria, cold skin, depressed mental status) (60), RHC
is recommended to confirm the presence of shock by hemody-
namic criteria and to assess filling pressures, thereby distin-
guishing cardiogenic from other forms of shock, in particular,
hypovolemic shock. However, there are no randomized studies
that address the benefit of RHC in this patient population. A
nonrandomized study by Gore et al. (20) demonstrated excess
mortality in all patients with acute myocardial infarction
treated with RHC and no benefit in the subset of patients with
cardiogenic shock. In that retrospective study, physician selec-
tion of the sicker patients to undergo RHC was likely. Simi-
larly, Zion et al. (21) observed increased mortality in all
patients with acute myocardial infarction managed with RHC
but no difference in patients with cardiogenic shock. The study
of Blumberg et al. (61), although not limited to patients with
hypotension or cardiogenic shock, reported increased mortal-
ity in Medicare patients with acute myocardial infarction
treated in hospitals with a higher rate of RHC.
The lack of observed benefit of RHC in the setting of
cardiogenic shock may be in part related to the poor prognosis
of these patients and the relative lack of effective treatment
options, such as vasoactive agents, IABP (62) and thrombolytic
agents (63) at the time these studies were carried out. Exper-
imental and clinical studies suggest that aggressive use of
IABP, often combined with thrombolysis, may improve prog-
nosis (64,65). More definitive forms of coronary revasculariza-
tion with percutaneous transluminal coronary angioplasty
(PTCA) (66–68) or CABG (60,69–71) have revealed some
encouraging results. The importance of the form of revascular-
ization and the timing of the procedure in patients in cardiogenic
shock are currently being studied by the international Should We
Emergently Revascularize Occluded Coronaries for Cardiogenic
Shock (SHOCK) trial (60). Although a preliminary report from
the registry of the SHOCK study (71) revealed a reduced
mortality associated with the use of RHC in patients with
suspected cardiogenic shock, there was substantial selection bias
in that patients receiving RHC were younger and were also more
likely to receive more aggressive management with IABP, cardiac
catheterization, PTCA and CABG.
Acute mechanical complications. MITRAL REGURGITATION
SECONDARY TO PAPILLARY MUSCLE RUPTURE. The presence of a
flail mitral valve leaflet may be suspected on the basis of
clinical presentation and physical examination, although in
severe cases characterized by low cardiac output, the systolic
murmur may not be heard because of rapid equalization of left
ventricular and left atrial pressures (72,73). Acute mitral
regurgitation can be accurately diagnosed by either trans-
thoracic echocardiography or TEE; the latter is superior for
detection of papillary muscle rupture (74). Severe mitral
regurgitation associated with papillary muscle rupture usually
prompts immediate cardiac catheterization (including RHC)
to evaluate coronary anatomy before emergent surgical inter-
vention. Bedside RHC is useful for guiding vasodilator, ino-
tropic and intraaortic balloon therapy (75). On the basis of
available published reports and experience, short-term RHC is
useful for guiding therapy in patients who are not surgical
candidates because of comorbidity or other reasons.
MITRAL REGURGITATION SECONDARY TO PAPILLARY MUSCLE
ISCHEMIA. Papillary muscle dysfunction without mechanical
disruption of the valve leads to mitral regurgitation, which may
be transient. The clinical diagnosis may be confirmed by
echocardiography with Doppler imaging. Treatment with anti-
ischemic, diuretic and vasodilator agents can reduce ventricu-
lar size and alter ventricular geometry (76) and may diminish
or eliminate mitral regurgitation. Bedside RHC is not required
for diagnosis and may in fact be misleading. Although the
presence of a “regurgitant” v wave on the PAOP tracing
supports the diagnosis of mitral regurgitation, the height of the
v wave often does not give an accurate assessment of the
severity of the mitral regurgitation, and large v waves are not
diagnostic of mitral regurgitation (77,78). Short-term hemody-
namic monitoring is helpful in assessing therapeutic interven-
tions, but the utility of RHC over clinical and echocardio-
graphic assessment has not been studied in this setting.
VENTRICULAR SEPTAL RUPTURE. Echocardiography with
Doppler imaging is highly sensitive and specific for the diag-
nosis of ventricular septal defect and provides information
regarding the magnitude of the shunt, pulmonary artery pres-
sure and right ventricular function. RHC, although useful for
the diagnosis of postinfarction septal rupture (79), is in general
not required. However, RHC is helpful for the assessment of
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the magnitude of the shunt (when not measurable by echocar-
diography), evaluation of the response of the shunt to phar-
macologic and IABP therapy and monitoring of patients in the
postoperative period.
VENTRICULAR FREE WALL RUPTURE. Free wall rupture may
present as (1) electromechanical dissociation; (2) subacute
rupture with tamponade and a low output/shock state; or (3)
pseudoaneurysm with or without hemodynamic instability.
Rupture with electromechanical dissociation usually results in
death before any attempt at premortem diagnosis. After
subacute cardiac rupture, echocardiography with Doppler im-
aging is the primary modality for the diagnosis of pericardial
effusion and tamponade and may guide pericardiocentesis.
Echocardiography may also detect the presence of a pseudo-
aneurysm. RHC can confirm the diagnosis of pericardial
tamponade in patients with suspected subacute cardiac rupture
(80), in whom clinical, electrocardiographic (81) and echocar-
diographic features are not diagnostic. However, RHC should
not delay potentially life-saving treatment.
Right ventricular infarction. Right ventricular dysfunction is
a common complication of inferior wall myocardial infarction
that can affect treatment and prognosis. The diagnosis of right
ventricular infarction can be made by physical examination and
electrocardiography, using right precordial leads (82); it can be
confirmed by echocardiography or radionuclide imaging (83).
Although several hemodynamic criteria have been proposed for
the diagnosis of right ventricular infarction (84), RHC is usually
not required for the diagnosis. Most patients with right ventricular
infarction remain hemodynamically stable, although caution in
the administration of nitrates and other vasodilators is recom-
mended to avoid reduced filling of the impaired, volume-sensitive
right ventricle (85). The degree of hemodynamic compromise
depends on the extent of left and right ventricular as well as right
atrial involvement (86,87). Furthermore, ventricular interaction
through septal shift and pericardial restraint can markedly affect
the systolic and diastolic function of both ventricles.
For patients with right ventricular infarction with hypoten-
sion and signs of low cardiac output, treatment includes
cautious volume loading, low doses of inotropic agents and, if
required, temporary (usually atrioventricular sequential) pac-
ing (88). RHC is not required in the majority of these patients.
Reperfusion of the infarct-related artery by either thromboly-
sis or catheter-based intervention can lead to rapid hemody-
namic improvement (89,90). The degree of volume loading
needed is controversial because excessive volume may result in
a decline in cardiac output (88,91). Therefore, in patients with
persistent hypotension or with low cardiac output despite
initial treatment, RHC is indicated with particular attention to
cardiac output measurements. Because of the alteration of the
diastolic properties of the left ventricle caused by ventricular
interaction and pericardial restraint, PAOP is not an accurate
indicator of left ventricular preload (86). Careful monitoring of
the effect of interventions on cardiac output is necessary.
Heart failure. RHC has not been shown to be effective for
the diagnosis and guidance of management of congestive heart
failure (CHF) in normotensive patients with acute myocardial
infarction. Zion et al. (21) demonstrated increased mortality in
patients with CHF receiving RHC, although there was no
difference in mortality when the investigators controlled for
severity of CHF. RHC in the patient with hypoxemia and
myocardial ischemia may pose an increased risk. Use of RHC
in patients with concurrent cardiac and pulmonary disease to
determine the contribution of left heart failure to respiratory
insufficiency and the use of RHC in patients with decompen-
sated heart failure were discussed earlier under “Heart Failure.”
Expert opinion of the Committee. Some guidelines for
RHC in patients with acute myocardial infarction were pro-
vided in 1996 by the Report of the ACC/AHA Task Force on
Practice Guidelines (Committee on Management of Acute
Myocardial Infarction) (6).
In the setting of acute myocardial infarction with hemody-
namic instability, the use of RHC depends on the underlying
cause and the course of hemodynamic compromise. RHC is
not required in patients with transient hypotension that re-
sponds promptly to either intravascular volume expansion or
low doses of inotropic drugs, or both. In patients who do not
improve rapidly, RHC is recommended to confirm the diag-
nosis of cardiogenic shock and to guide the assessment of the
short-term response to inotropic, vasodilator and diuretic
treatment or mechanical support (IABP). Similarly, transient
hypotension in the setting of right ventricular infarction can
often be managed without RHC. However, when hemody-
namic compromise persists despite initial therapy, RHC is
particularly important to monitor response of cardiac output to
volume loading and other therapeutic measures.
In the setting of hemodynamic instability caused by struc-
tural complications after acute myocardial infarction, echocar-
diography with Doppler imaging is the primary procedure for
diagnosis. The presence of acute mitral regurgitation with or
without valve disruption, ventricular septal rupture or pericar-
dial effusion or tamponade can be diagnosed rapidly by this
modality. The major indications for RHC relate to hemody-
namic monitoring of preoperative and postoperative pharma-
cologic interventions and mechanical (IABP) support.
In patients with heart failure or pulmonary edema (includ-
ing those requiring mechanical ventilation) and in patients with
right ventricular infarction without persistent hypotension, the
use of RHC for the guidance of pharmacologic therapy
represents an intermediate indication for which considerable
disagreement exists. Furthermore, RHC over a longer period
of time is controversial in patients with persistent hemody-
namic instability who are not considered for coronary revascu-
larization or surgical repair of structural complications.
Recommendations: Acute Myocardial Infarction
Conditions in which there is general agreement that RHC
is warranted
1. Differentiation between cardiogenic and hypovolemic shock
when initial therapy with intravascular volume expansion
and low doses of inotropic drugs has failed.
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2. Guidance of management of cardiogenic shock with phar-
macologic and/or mechanical support in patients with and
without coronary reperfusion therapy.
3. Short-term guidance of pharmacologic and/or mechanical
management of acute mitral regurgitation (with or without
disruption of the mitral valve) before surgical correction.
4. Establishment of severity of left to right shunting and
short-term guidance of pharmacologic and/or mechanical
management of ventricular septal rupture before surgical
correction.
5. Guidance of management of right ventricular infarction
with hypotension and/or signs of low cardiac output not
responding to intravascular volume expansion, low doses of
inotropic drugs and/or restoration of heart rate and atrio-
ventricular synchrony.
6. Guidance of management of acute pulmonary edema not
responding to treatment with diuretic drugs, nitroglycerin
and other vasodilator agents and low doses of inotropic
drugs.
Conditions in which reasonable differences of opinion exist
regarding RHC
1. Guidance of ongoing management of hypotension respond-
ing to initial therapy with intravascular volume expansion
and/or low doses of inotropic drugs.
2. Short-term guidance of pharmacologic and/or mechanical
management of acute mitral regurgitation if operation is
delayed or not contemplated.
3. Establishment of severity of left to right shunting, and
short-term guidance of pharmacologic and/or mechanical
management of ventricular septal rupture if operation is
delayed or not contemplated.
4. Guidance of management of right ventricular infarction,
after correction of hypotension and/or signs of low cardiac
output by intravascular volume expansion, low doses of
inotropic drugs and/or restoration of heart rate and atrio-
ventricular synchrony.
5. Guidance of management of acute pulmonary edema with
vasodilator agents and/or inotropic drugs after initial treat-
ment with diuretic drugs and nitroglycerin has failed.
6. Confirmation of the diagnosis of pericardial tamponade
associated with subacute myocardial rupture when clinical
and echocardiographic assessments are inconclusive.
Conditions in which RHC is not warranted
1. Guidance of management of postinfarction angina.
2. Guidance of ongoing management of pulmonary edema
responding promptly to treatment with diuretics and nitro-
glycerin.
3. Pericardial tamponade with marked hemodynamic instabil-
ity, when the diagnosis is certain or likely by clinical and/or
echocardiographic criteria, and RHC would delay treatment.
Conditions in which a relative contraindication to RHC
exists
Thrombolytic and/or anticoagulation therapy (for addi-
tional relative contraindications, see “Heart Failure,” above).
Conditions in which an absolute contraindication to RHC
exists
See “Heart Failure,” above.
Perioperative Use in Cardiac Surgery
Background. Patients undergoing cardiac surgery may de-
velop disturbances of perfusion postoperatively that can be life
threatening and/or place the function of vital organs at risk.
Identification of the underlying hemodynamic derangements
associated with impaired perfusion determines therapeutic
strategy. RHC facilitates both the diagnosis and management
of low cardiac output states, which may not always be ade-
quately assessed by clinical markers of perfusion after cardiac
surgery (92). Identification of abnormalities of cardiac output
as well as right and left ventricular afterload or preload is
particularly important to guide pharmacologic and other therapy
aimed at optimizing perfusion. For example, information from
RHC can be used to guide therapy with vasodilator, vasopressor
and inotropic drugs. Finally, cardiac surgical techniques involving
cardiopulmonary bypass may result in the accumulation of ex-
travascular lung water, and RHC often serves as a useful guide for
evaluating the effects of fluid management on global variables of
perfusion after cardiac surgery.
Observational studies suggest that RHC is beneficial in
cardiac surgical patients (93–96), although data collected from
such patients have not definitively established improvement in
outcome. Two large nonrandomized studies (97,98) have failed
to detect any significant difference in outcome after CABG
with RHC compared with central venous pressure monitoring
alone. In another study (99), small numbers of patients initially
randomized to undergo central venous pressure monitoring
alone for cardiac surgery were crossed over to the RHC group
because of the clinicians’ opinion that it would be unethical to
proceed without RHC in certain patients. The failure to
demonstrate any difference in outcomes between RHC and
central venous pressure monitoring may have been related to a
small sample size, as well as bias caused by group reassignment.
The use of RHC in cardiac surgery with particular emphasis
on CABG was recently discussed at the Pulmonary Artery
Catheter Consensus Conference (7) and at the National Heart,
Lung, and Blood Institute (NHLBI) and Food and Drug
Administration (FDA) workshop on pulmonary artery cathe-
terization and clinical outcomes (10). Both groups acknowl-
edged that available data for use of RHC in the perioperative
period are inconclusive because of methodologic difficulties.
The Committee of the Pulmonary Artery Catheter Consensus
Conference opined that the routine use of RHC does not
appear to be necessary in low risk patients undergoing cardiac
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surgery. They emphasized that RHC may be useful in high risk
patients, particularly those with important left ventricular
dysfunction, and proposed clinical studies in this patient
category. The NHLBI and FDA workshop recommended a
randomized, controlled trial to evaluate the need for and safety
of RHC in low risk patients undergoing CABG.
Expert opinion of the Committee. In the absence of defin-
itive prospective, randomized trials of RHC in patients under-
going cardiac surgery, the recommendations of the Committee
are based on a consensus of expert opinion. Extensive clinical
experience indicates that RHC is useful in patients undergoing
cardiac surgery with previous evidence of ventricular dysfunc-
tion of any cause, complex coronary artery disease or valvular
disease (especially when it is associated with significant coro-
nary artery disease or pulmonary hypertension) and in patients
requiring repeat cardiac surgery. Hemodynamic measurements
obtained from RHC facilitate the management of patients
after heart surgery and can be helpful in guiding inotropic,
vasopressor, vasodilator and fluid therapy. RHC catheteriza-
tion is warranted to facilitate the differentiation of hemody-
namic abnormalities resulting in inadequate perfusion when-
ever therapeutic trials of intravascular volume expansion or
vasoactive agents fail or when initial empiric management
strategies are contraindicated because of inordinate risk (e.g.,
in patients with known severe ventricular dysfunction). The use
of RHC after cardiac surgery should be discontinued when the
benefit no longer outweighs the risks associated with catheter
residence. This is especially important in the case of valvular
surgery or heart transplantation, where infectious complica-
tions can have grave consequences.
Available data do not support the routine use of RHC after
cardiac surgery in hemodynamically stable patients with good
ventricular function. A rational alternative to routine RHC in
this patient category is insertion of central venous access,
which may be used as a conduit for RHC if hemodynamic
inadequacy should become manifest. Justification for this
approach includes the finding that no difference in measured
outcomes could be detected in a controlled observational study
of cardiac surgical patients who developed a hemodynamic
“need” for RHC after initial monitoring with central venous
cannulation alone (98). Alternative methods for the evaluation
of cardiac function, such as echocardiography, should also be
considered, although continual monitoring of echocardio-
graphic variables in the postoperative period is not practical or
feasible with currently available technology (see “Alternatives
or Complementary Procedures,” below).
Recommendations: Perioperative Use in Cardiac Surgery
Conditions in which there is general agreement that RHC
is warranted
1. Differentiation between causes of low cardiac output (hy-
povolemia vs. ventricular dysfunction), when clinical and/or
echocardiographic assessment is inconclusive.
2. Differentiation between right and left ventricular dysfunc-
tion and pericardial tamponade, when clinical and/or echo-
cardiographic assessment is inconclusive.
3. Guidance of management of severe low cardiac output
syndromes.
4. Diagnosis and guidance of management of pulmonary
hypertension in patients with systemic hypotension and
evidence of inadequate organ perfusion.
Conditions in which reasonable differences of opinion exist
regarding RHC
1. Guidance of inotropic and/or vasopressor therapy after
patients with significant cardiac dysfunction have achieved
hemodynamic stability.
2. Guidance of management of hypotension and evidence of
inadequate organ perfusion when a therapeutic trial of
intravascular volume expansion and/or vasoactive agents is
associated with moderate risk.
Conditions in which RHC is not warranted
1. Routine management of uncomplicated cardiac surgical
patients with good ventricular function and hemodynamic
stability.
2. Initial management of postoperative hypotension when a
therapeutic trial of volume expansion and/or vasoactive
agents is associated with low risk.
Conditions in which a relative or absolute contraindication
to RHC exists
See “Heart Failure,” above.
The role of RHC in the perioperative management of high
risk cardiac patients after noncardiac surgery is not discussed in
this Expert Consensus Document, with the exception of heart
failure (see “Heart Failure,” above). These issues have been
addressed by the practice guidelines of the ACC/AHA on
perioperative cardiovascular evaluation for noncardiac surgery
(3) and by the practice guidelines of the American Society of
Anesthesiologists on pulmonary artery catheterization (8).
Primary Pulmonary Hypertension
Background. Primary pulmonary hypertension (PPH) is a
life-threatening disease of unknown etiology that is character-
ized by persistent and usually progressive elevation of pulmo-
nary artery pressure and pulmonary vascular resistance. The
recent data from a multicenter registry (100) organized by the
National Institutes of Health (NIH) have shown that the
median survival after diagnosis is ,3 years, although rare
individual examples of spontaneous remission and prolonged
survival have been reported (101,102).
Although the clinical value of RHC in patients with sus-
pected or confirmed PPH has not been formally assessed by
randomized prospective clinical trials, RHC has been exten-
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sively used in such patients for (1) establishment of the
diagnosis and severity of pulmonary hypertension; (2) assess-
ment of prognosis based on hemodynamic parameters; and (3)
selection and assessment of response to pharmacologic agents
(100–105).
Diagnostic applications. For accurate assessment of the
severity of pulmonary hypertension and for establishing the
diagnosis of precapillary pulmonary hypertension, RHC is
required. Doppler echocardiography can be used to estimate
pulmonary artery systolic pressure in patients with at least mild
tricuspid regurgitation. However, measurement of PAOP,
which is essential to distinguish between postcapillary (elevat-
ed PAOP) and precapillary (normal PAOP) pulmonary hyper-
tension and to determine pulmonary vascular resistance, can-
not presently be accomplished without RHC. Several studies
(100–102) have shown that the outcome in PPH is closely
related to the severity of hemodynamic derangements identi-
fied by RHC. Hemodynamic variables predictive of poor
survival include mean pulmonary artery pressure .85 mm Hg,
right atrial pressure .20 mm Hg, cardiac index ,2.0 liters/min
per m2 and mixed venous oxygen saturation ,60% (100–103).
Therapeutic applications. Before the institution of long-
term pharmacologic therapy in PPH, targeted to produce
pulmonary vasodilation, the hemodynamic response to vasodi-
lator agents is usually determined by RHC. Several studies
(101,106–120a) have correlated the pattern of acute hemody-
namic response with long-term prognosis and the clinical
response to long-term vasodilator therapy.
The optimal response to vasodilator therapy is generally
considered to be a decrease in pulmonary artery pressure and
pulmonary vascular resistance and an increase in cardiac
output, without hypoxemia, tachycardia or an excessive de-
crease in systemic arterial pressure. Long-term vasodilator
therapy is also considered when there is a decrease only in
pulmonary vascular resistance, without a major decrease in
pulmonary artery pressure. A substantial (20% to 30%) reduc-
tion in pulmonary vascular resistance in response to acute
vasodilator therapy has been shown to predict an improved
outcome (109,115,116). Adverse hemodynamic responses in-
clude reduction of cardiac output and systemic arterial pres-
sure and an increase in right atrial pressure, suggesting right
ventricular failure. Such responses are regarded as contraindi-
cations to long-term vasodilator therapy. Responders and
nonresponders can be identified only by careful hemodynamic
evaluation with RHC. It is particularly important to emphasize
that empiric treatment of patients with PPH with vasodilator
agents, including oral calcium channel blockers, can be haz-
ardous (113). However, it has been observed (118) that the
lack of a beneficial hemodynamic response to acute intrave-
nous administration of prostacyclin does not necessarily imply
lack of favorable response during long-term therapy.
Technical considerations. Performance of RHC in patients
with pulmonary hypertension may be difficult, particularly in
patients with right heart dilation and tricuspid regurgitation.
Fluoroscopic guidance of RHC may be useful. An increased
risk of pulmonary artery rupture, related to inflation of the
catheter tip balloon when advanced too far distally, has been
observed. Therefore, placement of the catheter tip in the
proximal pulmonary artery has been recommended. Use of a
guide wire balloon flotation catheter facilitates its placement
and reduces the frequency of dislodgment from the pulmonary
artery.
Recommendations: PPH
Conditions in which there is general agreement that RHC
is warranted
1. Exclusion of postcapillary (elevated PAOP) causes of pul-
monary hypertension.
2. Establishment of diagnosis and assessment of severity of
precapillary (normal PAOP) pulmonary hypertension.
3. Selection and establishment of safety and efficacy of long-
term vasodilator therapy based on acute hemodynamic
response.
4. Assessment of hemodynamic variables before lung trans-
plantation.
Conditions in which reasonable differences of opinion exist
regarding RHC
1. Evaluation of long-term efficacy of vasodilator therapy,
particularly prostacyclin.
2. Exclusion of significant left to right or right to left intracar-
diac shunt.
Conditions in which RHC is not warranted
None.




Complications related to RHC are associated with the
establishment of central venous access, the catheterization
procedure itself and catheter residence. Adverse events related
to central venous cannulation include arterial puncture, bleed-
ing at the site of insertion, nerve injury, pneumothorax and air
embolism. These events may occur with any central venous
cannulation and are not unique to RHC (121).
The primary complications related to the RHC procedure
itself are arrhythmias, which are usually minor in nature
(premature ventricular or atrial contractions) and resolve
spontaneously after the catheter is advanced through the right
heart into the pulmonary artery. Clinically insignificant ven-
tricular arrhythmias, usually not requiring therapy, have been
reported to occur in ;30% to 60% of patients during RHC
(121,122). Sustained ventricular arrhythmias requiring treat-
ment occur much less commonly (121,123–125) and primarily
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occur in patients with myocardial ischemia or myocardial
infarction or preexisting ventricular arrhythmias. RHC can
also occasionally precipitate right bundle branch block; in
patients with preexisting left bundle branch block, this can
result in complete heart block (126). On rare occasions,
knotting of the catheter can occur during insertion (127),
emphasizing the importance of fluoroscopic evaluation of the
catheter position after the procedure.
Arguably, the most serious complications of RHC are
related to catheter residence. They include pulmonary artery
rupture (128–131), thrombophlebitis (132), venous or intracar-
diac thrombus formation (132,133), pulmonary infarction
(134,135), endocarditis (136,137) and other catheter-related
infections (121,136,138). Risk factors for pulmonary artery
rupture include pulmonary hypertension and recent cardiopul-
monary bypass (139,140). The incidence of pulmonary infarc-
tion of embolic, thrombotic or ischemic origin has been
reported to be 0% to 1.3% (134,135). The risk of thrombotic
and infectious complications increases with duration of cathe-
ter residence (136). Most data suggest that the risk of infection
increases significantly when catheters remain in place .3 to 4
days (121,141). Local infection (catheter colonization) has
been observed in 18% to 63% of patients with catheters in
place for an average of 3 days, whereas bloodstream infection
has been documented in up to 5% of cases with a similar
duration of catheterization (141).
Alternative or Complementary Procedures
Echocardiography with Doppler imaging is the most impor-
tant alternative or complementary procedure to RHC in the
critically ill patient. Although echocardiography has not been
validated for widespread clinical use as an alternative to RHC
for estimation of left heart filling pressure, stroke volume and
cardiac output, it provides a wealth of complementary infor-
mation regarding global and regional abnormalities of left and
right ventricular function, cardiac chamber size, valvular le-
sions, ventricular wall thickness and pericardial structure and
function, in particular, the presence and physiologic signifi-
cance of pericardial effusion. In the severely ill patient, TTE
may be limited by lack of cooperation of the patient, mechan-
ical ventilation and other factors, in which case TEE is
superior. When performed with careful sedation and close
monitoring, TEE has a very low complication rate, even among
the most seriously ill patients (142–144), when used with
appropriate caution.
Echocardiographic acquisition of anatomic and physiologic
data. Hypotension and shock. Echocardiography can eluci-
date the likely mechanism of hypotension and shock (143,145).
Assessment of ventricular and valvular function aids in the
differentiation of patients with cardiogenic from those with
noncardiogenic shock (146). The presence and hemodynamic
significance of pericardial effusion can be determined by the
assessment of right ventricular wall motion and variation of
transmitral flow (147,148).
Mechanical complications of myocardial infarction. MITRAL
REGURGITATION. TTE is 100% sensitive for the detection of
mitral regurgitation resulting from papillary muscle rupture,
infarction or ischemia and in distinguishing it from ventricular
septal defect (149). The degree of mitral regurgitation and the
effectiveness of therapy can be evaluated by echocardiography
(150).
VENTRICULAR SEPTAL RUPTURE. Ventricular septal rupture
can be detected by TTE and Doppler imaging with a sensitivity
.90% (74,149,151). Helmcke et al. (152) demonstrated at
cardiac surgery a correlation between the width of the jet and
the size of the defect. When TTE imaging is suboptimal, TEE
is highly accurate (74). In the absence of valvular regurgitation,
the degree of left to right shunting can be estimated by Doppler
calculation of right and left ventricular stroke volumes (153).
VENTRICULAR FREE WALL RUPTURE. Ventricular free wall
rupture, which may be associated with pericardial tamponade,
can be suspected or diagnosed by echocardiography. Throm-
bus in the pericardial space supports the diagnosis. Echocar-
diography has a high sensitivity for the diagnosis of the
subacute form of cardiac rupture, revealing findings of (some-
times localized) pericardial effusion and associated tamponade
(154). A pseudoaneurysm, resulting from subacute rupture,
can be suggested by echocardiography (155), although it may
be difficult to differentiate from a true aneurysm (156). Dopp-
ler flow imaging demonstrates a characteristic flow pattern in and
out of the pericardial cavity at the site of the tear (151,157).
Right ventricular infarction. Echocardiography supports the
diagnosis of right ventricular infarction (158). Abnormal right
ventricular wall motion in the presence of an inferoposterior
myocardial infarction is diagnostic of this event. The presence
of normal or only mildly impaired left ventricular systolic
function is suggestive of the need for intravascular volume
expansion as initial therapy. In the setting of a large right
ventricular infarction with right ventricular failure, a right to
left shunt across a patent foramen ovale can be detected by
Doppler imaging (159).
Doppler estimation of cardiac pressures and stroke vol-
ume. Pulmonary artery pressure. Several studies (160–162)
have demonstrated the utility of Doppler echocardiography to
obtain hemodynamic information in patients with cardiac
disease. In patients with at least a minor degree of tricuspid
regurgitation, the difference between right ventricular systolic
pressure and right atrial pressure may be estimated by Doppler
echocardiography from the simplified Bernoulli equation
(163). Right atrial pressure may be estimated from clinical
examination (or measured by central venous pressure moni-
toring) or assigned an “average” value such as 10 mm Hg
(164). Pulmonary artery systolic pressure can thus be estimated
as the sum of the transtricuspid gradient and right atrial
pressure because in the absence of pulmonary outflow obstruc-
tion, pulmonary artery and right ventricular systolic pressures
are equal.
Left ventricular filling pressure. Considerable effort has been
directed at estimating left ventricular filling pressure, assessed
by Doppler ultrasound from the pattern of left ventricular
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filling (165,166). The peak rate of early diastolic filling of the
ventricle (E), the E wave deceleration time, the ratio of early
to late filling (E/A), the isovolumic relaxation time (IVRT) and
the atrial filling fraction are all related to the filling pressure
but are also affected by the intrinsic diastolic properties of the
ventricle (16). Rossvoll and Hatle (167) demonstrated that an
elevated left ventricular filling pressure (PAOP .15 mm Hg)
could be predicted with 85% sensitivity by examining both the
pulmonary venous and transmitral A waves. None of these
techniques for noninvasive estimation of left ventricular filling
pressure are used routinely, and they remain the subject of
continued clinical investigation.
Stroke volume. Doppler echocardiography can be used to
calculate stroke volume. Calculation is accomplished by inte-
grating the area under the flow velocity integral across any of
the four cardiac valves and multiplying this value by the
cross-sectional area of the annulus at which the measurement
is obtained. Although not widely applied to critically ill pa-
tients, these measurements have been shown (168,169) to be
reproducible and to correlate well with measurements ob-
tained by RHC. Application of these principles allows for
calculation of the regurgitant fraction (170) and the magnitude
of intracardiac shunts (Qp/Qs) (171). However, more experi-
ence is needed before these techniques can be applied in
widespread clinical practice.
TEE in the perioperative period. TEE is used extensively
before, during and after cardiac surgery (172–174). TEE plays
an important role in evaluating left ventricular function and
the results of valve repair. Echocardiographic assessment is of
particular value in the patient with hypotension and low
cardiac output during separation from cardiopulmonary by-
pass. In this setting, TEE can be used to determine the likely
cause of hypotension, differentiating among causes such as
abnormal left ventricular systolic function, mitral insufficiency
and an underfilled left ventricle.
A variety of promising developments, including miniatur-
ized probes and techniques for real time on-line monitoring of
ventricular volumes, ejection fraction and compliance, may
further enhance the role of cardiac ultrasound in the periop-
erative period. Although of promise, these techniques have not
been validated for clinical use.
Cost-Effectiveness of RHC
Cost-effectiveness analysis can be used to compare compet-
ing forms of therapy or courses of medical care and can offer
a cost-effectiveness ratio, best expressed in cost per quality-
adjusted life-year gained (175). This ratio for a specific inter-
vention may then be compared with ratios for other interven-
tions competing for scarce health care resources. To perform
such analysis, it is necessary to measure both the effect and cost
of the medical intervention and then extrapolate short-term
results over a lifetime, to derive the cost per quality-adjusted
life-year gained. In the case of RHC, to establish truly compa-
rable groups that would provide usable cost and efficacy data,
it would be necessary to conduct randomized trials. However,
as noted below, such trials may be difficult to conduct success-
fully in homogeneous populations.
Given these difficulties, there is limited information permit-
ting evaluation of the cost-effectiveness of RHC. If, in some
patients, there is clinical benefit at reduced cost, then RHC is
clearly indicated. In patients in whom there is decreased or
negative benefit, the procedure is not indicated regardless of
cost. In patients in whom there is benefit at increased cost, a
formal cost-effectiveness analysis may help in deciding whether
to place a right heart catheter. At least one attempt to provide
a theoretic evaluation of the cost-effectiveness of RHC in
patients undergoing CABG has been published (176). Further
research may help to define the cost-effectiveness of RHC in
different patient groups, especially those in which the value of
RHC is currently controversial.
Proposals for Randomized Trials
The Expert Consensus Committee considered carefully the
role of future research for evaluation of the safety and efficacy
of RHC in patients with cardiac disease. It identified two areas
in which RHC is frequently used and randomized trials may be
considered, namely, heart failure and cardiac surgery. The
Committee came to the following conclusions:
Randomized trials in heart failure. Randomized clinical
trials in patients with heart failure are ethical in those subsets
(e.g., patients with severe heart failure who require titration of
diuretic, vasodilator and inotropic therapy) for which reason-
able differences of opinion exist regarding the indication for
RHC. Spodick (177) has suggested that a panel of three
experts be formed in each participating hospital; randomiza-
tion would be permissible only if there were a disagreement
among the three experts as to whether RHC was indicated in
an individual patient. Although such an approach would be
difficult, it would facilitate and support recruitment of appro-
priate patients for such a trial. For consideration of sample size
and power, end points other than mortality would be neces-
sary. End points should also include morbidity, length of ICU
and total hospital stay and cost. Optimal use of RHC should be
examined, with attention to 1) appropriateness of indications;
2) skill of personnel; 3) accuracy of measurements; 4) skill in
interpretation of measurements; and 5) management algo-
rithms based directly on RHC measurements. For the benefit
of RHC to be assessed, it must be deployed in clinical
conditions for which beneficial treatment is available. Patients
should be stratified according to whether heart failure is acute
or chronic and whether shock is present.
A multicenter trial on the effectiveness of RHC in patients
with persistent or refractory CHF has been proposed at the
recent NHLBI/FDA Workshop on Pulmonary Artery Cathe-
terization and Clinical Outcomes (10).
Randomized trials in cardiac surgery. RHC is commonly
performed as a routine part of CABG and other cardiac
surgery. At present, the routine use of RHC for low risk
patients (normal ventricular function and hemodynamically
stable) cannot be viewed as warranted. In principle, the routine
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use of RHC could be established after an appropriate clinical
trial. However, such a trial would be difficult to perform
because the event rates are low in this patient category, and the
impact of RHC is likely to be small. In low risk patients, for
whom the mortality rate may be ,21%, RHC would be
expected to have minimal benefit and might add risk. RHC is
even less likely to favorably affect other potential end points,
such as infection, stroke and myocardial infarction. Cost and
resource use could be considered an end point, but in the
absence of sufficient power for examining a clinical end point,
a cost-effectiveness study could not be reasonably performed.
However, if clinical outcome is considered likely to be equiv-
alent with or without the use of RHC, then a pure cost study
(i.e., a cost minimization study) would be possible.
A clinical trial in high risk patients undergoing cardiac
surgery is potentially more likely to be revealing because the
incidence of end points will be much higher, and the potential
of RHC to affect outcome would appear to be much greater
than a trial in low risk patients. Clinical studies in this patient
category have been recently proposed by the Pulmonary Artery
Catheter Consensus Conference (7). However, the Expert
Consensus Committee of this document is concerned that such
a trial is difficult to perform because the clinical situation is not
in equipoise. Anesthesiologists and cardiac surgeons in this
situation are likely to regard RHC as useful, making patient
enrollment difficult. Should such a trial be performed, a
reasonable primary clinical end point will need to be identified,
with cost and resources use as secondary end points. Because
mortality is not likely to vary enough between treatment arms
to permit adequate statistical power at a reasonable sample
size, it will be necessary to nominate a different clinical end
point or composite of end points.
Summary. Although it is possible in principle to perform
clinical trials in patients with heart failure undergoing cardiac
surgery, the obstacles are considerable. Randomized trials
most commonly assess therapeutic interventions. RHC, in
contrast, is a diagnostic technique that may result in multiple
changes in therapeutic strategies, from relatively minor (e.g.,
changing diuretic agents) to major (e.g., a decision on the need
for cardiac surgery of even transplantation). Sample sizes
supporting the selection of mortality as the primary end point
would be unreasonably large. Given the difficulties noted
above, the most compelling case can probably be made for a
trial involving the role of RHC in the management of refrac-
tory decompensated heart failure.
Frequency of Use of RHC
There are presently no good data available regarding the
frequency of use of bedside RHC in cardiac practice. Data
provided by industry revealed an annual sale of ;1.5 million
(Swan-Ganz) catheters in the United States, with estimates
that 30% of catheters are used in cardiac surgery, 30% in
cardiac catheterization laboratories and coronary care units,
25% in high risk surgery and trauma and 15% in medical ICUs
(George Sopko, MD, NHLBI, personal communication, 1997
[to B. Bernard, Baxter Health Care Corporation]). A question
on the frequency of use of Swan-Ganz catheters was included
in the 1997 ACC Membership Profile. This survey is mailed
biannually to all ACC members to ascertain selected member
attributes, including practice characteristics and educational
interests. The 1997 Membership Profile achieved a response
rate of 59% (11,502 questionnaires returned out of 19,421
mailed). Respondents were asked to indicate how many times
a year they performed Swan-Ganz catheterization in patients
with cardiac disease (excluding use in the medical ICU and
surgery). The question was answered by 6,985 respondents.
Five frequency of use categories were available: category 1 5
None; category 2 5 1 to 50; category 3 5 51 to 100; category
4 5 101 to 150; and category 5 5 more than 150. Most
respondents (65%) indicated that they performed between 1
and 50 Swan-Ganz catheterizations/year. Respondents self-
identified as either invasive or interventional cardiologists
reported the highest frequency of Swan-Ganz catheterizations
in the 1 to 50 range (72% vs. 61% for all other respondents).
The differential in frequency of use between this group of
invasive or interventional cardiologists and other cardiovascu-
lar practitioners was greater in the higher frequency of use
categories (26% vs. 9% for procedure frequencies .50/year).
These data cannot address whether use in the 1 to 50 category
is more skewed to the lower or higher part of this range.
Conclusions
The Expert Consensus Committee was convened to formu-
late recommendations for the use of bedside RHC in patients
with known or suspected cardiac disease. Because few data are
available from well controlled clinical trials, the recommenda-
tions are based primarily on inferences from published reports
and expert opinion. The use of RHC over the past quarter
century has fostered major advances in the diagnosis and
treatment of critically ill cardiac patients. The role of RHC is
currently in transition because of the availability of noninvasive
diagnostic techniques, in particular, echocardiography with
Doppler imaging, which in some cases complements and in
others is an alternative to RHC. RHC has a primary role in
management of heart failure in certain patients in whom 1) the
diagnosis of heart failure is uncertain; 2) heart failure is of
sufficient severity to require intensive pharmacologic manage-
ment; or 3) heart transplantation is contemplated. In patients
with acute myocardial infarction, echocardiography has a
primary role in the diagnosis of mechanical complications, and
RHC is helpful in certain instances for assessment of the
severity of hemodynamic compromise and the response to
therapy. The Committee does not recommend the routine use
of RHC in uncomplicated cardiac surgical patients with good
ventricular function and hemodynamic stability.
Although the Committee recognizes the interest in random-
ized clinical trials for establishing the safety and efficacy of
RHC, it is not optimistic that such studies will be feasible. The
challenge of controlling for the effects of therapeutic interven-
tions based on the diagnostic modality of RHC while achieving
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adequate statistical power in well defined patient subgroups
will be difficult to meet. A possible exception would be a study
of the efficacy of RHC in the management of patients with
refractory decompensated heart failure. The Committee ques-
tions whether major resources should be devoted to reevalua-
tion of the role of RHC or whether such resources would be
better directed toward further development and evaluation of
semi-invasive or noninvasive diagnostic techniques, including
echocardiography with Doppler imaging.
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